PX-12

For research use only. Not for use in humans.

目录号:S7947 别名: DB05448, 1-methyl propyl 2-imidazolyl disulfide

PX-12 Chemical Structure

CAS No. 141400-58-0

PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide)是一种有效的 thioredoxin-1 (Trx-1) 抑制剂,作用于 Trx-1 上 Cys73 的不可逆硫代烷基化。Phase 2。

规格 价格 库存 购买数量  
RMB 794.43 现货
RMB 3087.63 现货
RMB 7182.63 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的PX-12发表文献6篇:

产品安全说明书

Thioredoxin抑制剂选择性比较

生物活性

产品描述 PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide)是一种有效的 thioredoxin-1 (Trx-1) 抑制剂,作用于 Trx-1 上 Cys73 的不可逆硫代烷基化。Phase 2。
靶点
Trx-1 [1]
()
体外研究

在MCF-7和HT-29细胞中,PX-12防止低氧(1% 氧气)诱导的HIF-1alpha蛋白增加,并降低HIF-1反式激活活性,VEGF形成,和诱导型一氧化氮合酶。PX-12也会抑制MCF-7和HT-29细胞的生长,IC50s分别为1.9 μM和2.9μM。[1] PX-12也会通过Nrf2/PMF-1介导的增加抑制HIF-1α蛋白质水平。[2]在A549细胞中,PX-12通过G2/M细胞周期阻滞,和Bax-介导的,ROS-依赖性细胞凋亡抑制细胞生长。[3]在肝癌细胞中,PX-12与5-FU发挥协同作用,显著抑制致瘤性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T84 NYn3eo55TnWwY4Tpc44h[XO|YYm= MVyzJIhzew>? Ml\NTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCC2aHnvdoVld3irbj3t[YRq[XSnZDDUS|Ih[WO2aY\heIlwdiCneIDy[ZN{\WRiaX6gWFg1KGOnbHzzJIF{e2W|c3XkJIF{KGKub3PrZYRmKG:oIEWtZolwfGmwYX3p[I9x\W62eXzhcYlv\SCrbnPvdpBwemG2aX;uJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBucWO{b4Pjc5Bq[yCjbnHsfZNqeyxiSVO1NF0zNjFzzszN M{i5b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{K3OlU3Lz5{M{OyO|Y2PjxxYU6=
MEF M{PhdWN6fG:2b4jpZ4l1gSCjc4PhfS=> NHy3UZdEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBOTUZiY3XscJMtKEyGNUC9Nk44|ryP NHzaUlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
Ramos MmnUR5l1d3SxeHnjbZR6KGG|c3H5 M{\sZVczKGi{cx?= MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSZY1weyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBNTDVyPUOuOO69VQ>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF{OEi3Okc,OjJzMki4O|Y9N2F-
PancO2 NUHrSJNVS3m2b4TvfIlkcXS7IHHzd4F6 NVX6e3cyPzJiaILz M{LlWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJHBidmORMjDj[YxteyCjZoTldkA4OiCqcoOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnesJGxFPTB;Mz65{txO NI\xTnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
T24 NXO3[YF2S3m2b4TvfIlkcXS7IHHzd4F6 NXnZOXRiPzJiaILz M4XQWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHQzPCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFzEOVA:PC54zszN MlrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMki4O|YoRjJ{MUK4PFc3RC:jPh?=
B78 M3mxUWN6fG:2b4jpZ4l1gSCjc4PhfS=> NUjG[nlmPzJiaILz M3LYcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGI4QCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFzEOVA:Pc7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF{OEi3Okc,OjJzMki4O|Y9N2F-
CT26 M3v2S2N6fG:2b4jpZ4l1gSCjc4PhfS=> NYTGdVB5PzJiaILz MoL4R5l1d3SxeHnjbZR6KGGpYXnud5Qhf2muZDD0fZBmKG2xdYPlJGNVOjZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDMSFUxRTVwMt88US=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF{OEi3Okc,OjJzMki4O|Y9N2F-
K562 NEHGRZdEgXSxdH;4bYNqfHliYYPzZZk> NGK4SWo4OiCqcoO= MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGxFPTB;NT61{txO MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF{OEi3Okc,OjJzMki4O|Y9N2F-
M21 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NH2xNoxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF2yNUBk\WyuczygS2k2OD16LkROwG0> MnnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEK2N|koRjF6NUCyOlM6RC:jPh?=
MCF7 NIW4TG5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3zFRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczygS2k2OD16LkROwG0> MoraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEK2N|koRjF6NUCyOlM6RC:jPh?=
MCF7 M{fYRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Ml;sOFghcHK| M{f2dmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9PE4{|ryP MkHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4MUe0NVQoRjF6NkG3OFE1RC:jPh?=
M21 NX7DcWNvSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MofzOFghcHK| MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE1{MTDj[YxteyCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3SsJGdKPTB;OD6z{txO NULBSlZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2NVc1OTRpPkG4OlE4PDF2PD;hQi=>
Raji M{j2RWN6fG:2b4jpZ4l1gSCjc4PhfS=> MoPBO|IhcHK| Mkf3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVoFrcSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBNTDVyPUiuPO69VQ>? M3fTRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUK4PFc3Lz5{MkGyPFg4PjxxYU6=
EMT6 MmO0R5l1d3SxeHnjbZR6KGG|c3H5 NF;hOYw4OiCqcoO= NUjXWWd[S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTU2WNjDj[YxteyCjZoTldkA4OiCqcoOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnesJGxFPTB;MUGuOu69VQ>? NF;HRYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
HT29 MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MoD6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVEK5JINmdGy|LDDHTVUxRTJ3zszN M1juTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUCyOlM6Lz5zOEWwNlY{QTxxYU6=
HT29 NHrFV25CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= Mn\POFghcHK| NIW3c2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVI2|ryP MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZzN{SxOEc,OTh4MUe0NVQ9N2F-
M21 MoHnSpVv[3Srb36gZZN{[Xl? NIT3eZczPSCwTR?= NWXNVFlJOTZiaILz MlnaV5RqdXWuYYTpc44hd2ZiboXjcIVieiC2cnHud4xw[2G2aX;uJI9nKHSqaX;y[YRwgGmwLUGg[pJwdSCleYTvd49tKGmwIHj1cYFvKE1{MTDj[YxteyCjdDCyOUBvVSCjZoTldkAyPiCqcoOgZpkhcW2vdX7vZ5l1d2[udX;y[ZNk\W6lZR?= Mn31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4MUe0NVQoRjF6NkG3OFE1RC:jPh?=
Raji Mn34SpVv[3Srb36gZZN{[Xl? NGf6TWM2KHSxIEGwJJVO M2CwZVQhfG9iMkSgbJJ{ Ml7sTY5lfWO2aX;uJI9nKFS{eDDtVm5CKGW6cILld5Nqd25iaX6gbJVu[W5iUnHqbUBk\WyuczDheEA2KHSxIEGwJJVOKGGodHXyJFQhfG9iMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>? NGGyPYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
Raji MV7GeY5kfGmxbjDhd5NigQ>? M172SlExKHSxIEKwJJVO NWrJSpJLPCC2bzC4JIhzew>? NH7CUnVKdmS3Y4Tpc44hd2ZiVIL4JJBzd3SnaX6g[ZhxemW|c3nvckBqdiCqdX3hckBT[WqrIHPlcIx{KGG2IEGwJJRwKDJyIIXNJIFnfGW{IESgeI8hQCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NWXHW|Y2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNlg5PzZpPkKyNVI5QDd4PD;hQi=>
DAOY MmDudWhVWyCjc4PhfS=> NFPVVWVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 MoH3dWhVWyCjc4PhfS=> NHfNe4hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MoH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MVfxTHRUKGG|c3H5 M{nnfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| M4C4ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MUPxTHRUKGG|c3H5 NFrSOHdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NUHYU4d2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NIL3fmlyUFSVIHHzd4F6 M2XqUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 MkHxdWhVWyCjc4PhfS=> NFTKSZRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NEXnTYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 M3nQXZFJXFNiYYPzZZk> MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? NHTHR|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MlHsdWhVWyCjc4PhfS=> MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| Ml\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MkLrdWhVWyCjc4PhfS=> M2OwNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? M4HG[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) M2j3O5FJXFNiYYPzZZk> NFPxSZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 MknwdWhVWyCjc4PhfS=> M3Thd5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>? NXXvfmdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC M4TiRpFJXFNiYYPzZZk> NFHGWW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 MV\xTHRUKGG|c3H5 NHjaWZRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>? MnfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 M1njdZFJXFNiYYPzZZk> NFnqOo5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>? Ml[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 M1G2NJFJXFNiYYPzZZk> M2X3XJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> NFjqb4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) NGDMUJJyUFSVIHHzd4F6 NGfkSGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>? NVrXO41LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NHqxVHFyUFSVIHHzd4F6 MlP4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH NIfyT5dyUFSVIHHzd4F6 NHHUTVByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| MnHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

体内研究 在负荷MCF-7肿瘤异种移植物的小鼠中,PX-12 (12 mg/kg, i.p.)降低HIF-1α 与 VEGF蛋白质水平和微血管密度。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: MCF-7 和 HT-29 细胞
  • Concentrations: ~10 μM
  • Incubation Time: 72 小时
  • Method: 细胞生长使用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐法测量。在空气或低氧(1% 氧气)条件下,细胞在一系列浓度的PX-12或pleurotin中暴露16小时。然后细胞在空气中用温的不含药物的培养基洗涤,再进行后面的72小时培育。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 负荷MCF-7肿瘤异种移植物的小鼠
  • Dosages: 12 mg/kg
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (201.79 mM)
Water Insoluble
Ethanol '38 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
11mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 188.31
化学式

C7H12N2S2

CAS号 141400-58-0
储存条件 粉状
溶于溶剂
别名 DB05448, 1-methyl propyl 2-imidazolyl disulfide

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00736372 Completed Drug: PX-12 Metastatic Cancer|Advanced Cancer Cascadian Therapeutics Inc.|Seagen Inc. June 2008 Phase 1
NCT00417287 Terminated Drug: PX-12 Pancreatic Neoplasms Cascadian Therapeutics Inc.|National Cancer Institute (NCI)|Translational Genomics Research Institute|Seagen Inc. December 2006 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买PX-12 | PX-12供应商 | 采购PX-12 | PX-12价格 | PX-12生产 | 订购PX-12 | PX-12代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID